October 29, 2014 | The Israeli drug development company IntecPharma has secured Food & Drug Administration approval for a Phase III clinical trial on its Parkinson’s disease treatment. The Accordion Pill Levodopa is a gastro-retentive drug delivery system for the treatment of the common neurodegenerative disease. The company believes that the trial, which may be conducted together with a major pharmaceutical company, will be completed in the second half of 2015. IntecPharma is a publicly traded development stage biopharmaceutical company based in Jerusalem, Israel.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024

TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024

Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024

BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments